- Home
- NL vs ANNX Comparison
NL vs ANNX Comparison
Compare NL & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NL
- ANNX
- Stock Information
- Founded
- NL 1891
- ANNX 2011
- Country
- NL United States
- ANNX United States
- Employees
- NL N/A
- ANNX N/A
- Industry
- NL Major Chemicals
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- NL Industrials
- ANNX Health Care
- Exchange
- NL Nasdaq
- ANNX Nasdaq
- Market Cap
- NL 342.9M
- ANNX 362.4M
- IPO Year
- NL N/A
- ANNX 2020
- Fundamental
- Price
- NL $7.46
- ANNX $2.53
- Analyst Decision
- NL Sell
- ANNX Strong Buy
- Analyst Count
- NL 1
- ANNX 7
- Target Price
- NL $6.00
- ANNX $15.80
- AVG Volume (30 Days)
- NL 28.7K
- ANNX 1.0M
- Earning Date
- NL 03-06-2025
- ANNX 03-03-2025
- Dividend Yield
- NL 4.90%
- ANNX N/A
- EPS Growth
- NL N/A
- ANNX N/A
- EPS
- NL 1.38
- ANNX N/A
- Revenue
- NL $145,941,000.00
- ANNX N/A
- Revenue This Year
- NL $2.18
- ANNX N/A
- Revenue Next Year
- NL $2.50
- ANNX $429.34
- P/E Ratio
- NL $5.38
- ANNX N/A
- Revenue Growth
- NL N/A
- ANNX N/A
- 52 Week Low
- NL $5.20
- ANNX $2.30
- 52 Week High
- NL $9.42
- ANNX $8.40
- Technical
- Relative Strength Index (RSI)
- NL 56.26
- ANNX 35.83
- Support Level
- NL $6.28
- ANNX $2.47
- Resistance Level
- NL $7.79
- ANNX $2.83
- Average True Range (ATR)
- NL 0.42
- ANNX 0.23
- MACD
- NL 0.08
- ANNX 0.06
- Stochastic Oscillator
- NL 78.15
- ANNX 43.40
About NL NL Industries Inc.
NL Industries Inc operates in the component products industry through its majority-owned subsidiary, CompX International Inc. It manufactures engineered components that are sold to a range of industries, including recreational transportation, postal, office and institutional furniture, cabinetry, tool storage, healthcare, gas stations and vending equipment. CompX has three production facilities in the United States, through which it produces a precision ball bearing slide, security products, and ergonomic computer support systems. The company derives majority of its revenue from Europe.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.